Pancreatic Cancer Initial Detection Via Liquid Biopsy

The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient cohorts. For the entire series of these studies, the following groups are planned: 1) Histologically proven early-stage pancreatic cancer (e.g. T1a/b and T2 carcinomas [N0M0]); 2) Intraductal papillary mucinous neoplasia (IPMN) that were operated with verification of the benign, premalignant or malignant histology; 3) ordinary branched-duct IPMN; 4) individuals at risk (IAR) with and without IPMN, with and without known hereditary cancer gene (e.g. BRCA2); 5) a high risk group of patients with chronic pancreatitis, aged 55-65, who are heavy smokers (≥40 PY), with newly onset diabetes mellitus (NODM).

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Pancreatic Cancer Behavior Chronic Disease Chronic Pancreatitis Diabetes Mellitus Digestive System Diseases Digestive System Neoplasms Disease Attributes Endocrine Gland Neoplasms Endocrine System Diseases Glucose Metabolism Disorders IPMN, Pancreatic Individuals at Risk Metabolic Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Ductal, Lobular, and Medullary Neoplasms, Glandular and Epithelial Nutritional and Metabolic Diseases Pancreatic Diseases Pancreatic Intraductal Neoplasms Pancreatic Neoplasms Pancreatitis Pancreatitis, Chronic Pathologic Processes Pathological Conditions, Signs and Symptoms Smoking

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Gastrocentrum, KarolinskaUniversity Hospital

Stockholm, 14186, Sweden

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Suspicion of or elevated risk for pancreatic ductal adenocarcinoma (PDAC); intraductal papillary mucinous neoplasias (IPMN); individuals at risk (IAR) for pancreatic cancer

Exclusion criteria

other malignant condition

Treatment and study plan

Liquid Biopsy

Diagnostic Test

Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for "ground truth"

Primary outcomes

Cancer detection

Time frame: Up to 4 weeks after surgery

Liquid biopsy test(s) detecting pancreatic cancer on biobanked, archival samples of patients with histologically confirmed pancreatic lesions (PDAC, IPMN, pancreatitis).

Secondary outcomes

Overall survival

Time frame: 1 month - 24 months after surgical resection of the tumor

Overall survival

Sponsors and collaborators

Lead sponsor

Karolinska University Hospital

Other

Collaborators

Umeå University

Registry information

Acronym: PANCAID

Important dates

Study start: 2024
Primary completion: 2027
Study completion: 2027
First posted: Feb 28, 2024
Registry last updated: Apr 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting